Spero Therapeutics (SPRO) Tops Q4 EPS by 73c, Beats on Revenue

Spero Therapeutics (NASDAQ: SPRO) reported Q4 EPS of $0.53, $0.73 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $41.3 million versus the consensus estimate of $26 million.

For earnings history and earnings-related data on SmartPros Ltd. (SPRO) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Astrana Health (ASTH) Mentioned as short at Glass House
• Natural Gas Inventory 44 bcf vs 48 bcf Expected